Close Menu

NEW YORK (GenomeWeb) – Protagen said today it has entered a collaboration with the Gustave Roussy Institute of Oncology to identify biomarkers for immune system-related side effects in cancer patients treated with checkpoint inhibitors.

Under the collaboration, the parties will use Protagen's SeroTag platform, which simultaneously measures autoantibody levels for thousands of antigens, to test cancer immunotherapy patients for markers linked to immune-related adverse events (irAEs) and, ultimately, develop a risk-profiling test for patients undergoing immunotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.